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Pancreatic	   cancer	   remains	   a	   formidable	   challenge	   for	   oncologists	   and	   patients	   alike.	   Despite	   intensive	  
efforts,	  attempts	  at	   improving	  survival	   in	   the	  past	  15	  years,	  particularly	   in	  advanced	  disease,	  have	   failed.	  
This	  is	  true	  even	  with	  the	  introduction	  of	  molecularly	  targeted	  agents,	  chosen	  on	  the	  basis	  of	  their	  action	  
on	  pathways	  that	  were	  supposedly	   important	   in	  pancreatic	  cancer	  development	  and	  progression:	   indeed,	  
with	   the	   notable	   exception	   of	   the	   epidermal	   growth	   factor	   receptor	   (EGFR)	   inhibitor	   erlotinib,	   that	   has	  
provided	  a	  minimal	  survival	  improvement	  when	  added	  to	  gemcitabine,	  other	  agents	  targeting	  EGFR,	  matrix	  
metallo-­‐proteases,	   farnesyl	   transferase,	   or	   vascular	   endothelial	   growth	   factor	   have	   not	   succeeded	   in	  
improving	  outcomes	  over	  standard	  gemcitabine	  monotherapy	  for	  a	  variety	  of	  different	  reasons.	  However,	  
recent	   developments	   in	   the	   molecular	   epidemiology	   of	   pancreatic	   cancer	   and	   an	   ever	   evolving	  
understanding	  of	  the	  molecular	  mechanisms	  underlying	  pancreatic	  cancer	   initiation	  and	  progression	  raise	  
renewed	  hope	   to	   find	  novel,	   relevant	   therapeutic	   targets	   that	   could	  be	  pursued	   in	   the	  clinical	   setting.	   In	  
this	  review	  we	  focus	  on	  molecular	  epidemiology	  of	  pancreatic	  cancer,	  epithelial-­‐to-­‐mesenchymal	  transition	  
and	   its	   influence	   on	   sensitivity	   to	   EGFR-­‐targeted	   approaches,	   apoptotic	   pathways,	   hypoxia-­‐related	  
pathways,	  developmental	  pathways	  (such	  as	  the	  hedgehog	  and	  Notch	  pathways),	  and	  proteomic	  analysis	  as	  
keys	   to	   a	  better	  understanding	  of	  pancreatic	   cancer	  biology	   and,	  most	   importantly,	   as	   a	   source	  of	  novel	  
molecular	  targets	  to	  be	  exploited	  therapeutically.	  
	  	  	  
Introduction.	  
Pancreatic	   cancer	   is	   the	   8th	   and	   9th	   leading	   cause	   of	   cancer	   death	   in	   men	   and	   women,	   respectively,	  
worldwide	   and	   the	   4th	   leading	   cause	   of	   cancer	   death	   in	  Western	   countries	   [1,	   2].	  With	  mortality	   closely	  
approaching	  incidence	  (>40.000	  estimated	  new	  cases	  and	  approximately	  37.000	  estimated	  deaths	  in	  2010	  
in	  the	  US	  alone)	  and	  a	  5-­‐yr	  survival	  rate	  of	  5%	  overall	   [1],	  pancreatic	  cancer	  (and	   its	  most	  aggressive	  and	  
frequent	  histological	  subtype	  pancreatic	  ductal	  adenocarcinoma	  -­‐	  PDAC)	   is	  arguably	  the	  deadliest	  of	  solid	  
tumors.	  Moreover,	   progresses	   in	   PDAC	   treatment,	   especially	   in	   the	   advanced	  disease	   setting,	   have	  been	  
few	   and	   modest	   over	   the	   past	   20	   years	   [3,	   4],	   resulting	   in	   no	   significant	   improvement	   in	   5-­‐	   and	   10-­‐yr	  
survival	  expectations	  between	  1998	  and	  2003	  [5].	  Such	  a	  dismal	  picture	  recognizes	  a	  variety	  of	  causes,	  from	  
the	   lack	  of	  early	  biomarkers	  and	  cost/effective	  screening	  methods,	  resulting	   in	  diagnosis	  at	   late	  stages	  of	  
the	   disease,	   not	   amenable	   to	   curative	   surgery	   [4,	   1],	   to	   the	   inherent	   aggressiveness	   and	   resistance	   to	  
current	   therapeutic	   strategies	  of	  PDAC	  cells,	  particularly	   in	   their	  physiologic	  environment	  where	   they	  are	  
surrounded	  by	  a	  dense,	  desmoplastic	  stroma	  which	  supports	  their	  growth	  and	  dissemination	  and	  protects	  
them	   from	   conventional,	   and	   perhaps	   even	   from	   molecularly	   targeted,	   therapeutic	   agents	   [4,	   6,	   7].	   In	  
addition,	   although	   a	   core	   set	   of	   common	   genetic	   alterations	   that	   drive	   the	   transformation	   of	   pancreatic	  
ductal	   (or	   acinar)	   cells	   and	   the	  progression	   from	  precursor	   lesions	   (pancreatic	   intraepithelial	   neoplasia	  –	  
PanIN)	  to	  frankly	  invasive,	  disseminated	  PDAC	  have	  been	  precisely	  mapped	  [8,	  9,	  10],	  recent	  data	  depict	  a	  
much	  more	  complex	  genetic/molecular	   landscape.	   Indeed,	  a	  recent	  comprehensive	  genetic	  analysis	  of	  24	  
pancreatic	  cancers	  identified	  an	  average	  of	  63	  genetic	  abnormalities	  per	  tumor,	  that	  could	  be	  organized	  in	  
12	  different	  functional,	  cancer-­‐relevant	  pathways;	  moreover,	  key	  mutations	  in	  each	  pathway	  appeared	  to	  
differ	  from	  one	  tumor	  to	  another	  [11].	  
In	   this	   review,	  we	   analyze	   the	   results	   of	   clinical	   trials	   that	   have	   been	   conducted	   so	   far	  with	  molecularly	  
targeted	  agents	  in	  PDAC,	  speculating	  on	  possible	  reasons	  for	  their	  failure	  to	  improve	  survival	   in	  advanced	  
disease,	   and	   provide	   an	   overview	   of	   recent	   progresses	   in	   the	   understanding	   of	   the	   molecular	   bases	   of	  
pancreatic	  cancer,	  with	  a	  focus	  on	  novel	  potential	  targets	  for	  therapy.	  
	  Targeted	  therapies	  for	  pancreatic	  cancer:	  current	  status	  and	  meta-­‐analysis	  of	  randomized	  trials.	  
We	   have	   recently	   reported	   on	   the	   impact	   of	   combination	   therapy,	   including	   regimens	   employing	  
molecularly	  targeted	  agents,	  on	  survival	  of	  advanced,	  inoperable	  PDAC	  patients	  [3].	  In	  order	  to	  explore	  the	  
impact	  of	  agents	   targeting	   specific	  molecular	  pathways	   in	   such	  disease	   setting,	  we	  updated	  our	  previous	  
meta-­‐analysis	   including	   all	   fully	   published,	   phase	   III,	   prospective,	   randomized	   clinical	   trials	   enrolling	  
untreated	  patients	  with	  advanced	  PDAC,	  who	  were	  randomized	  to	  receive	  a	  targeted	  agent	  in	  addition	  to	  
standard	  gemcitabine	  monotherapy	  (TA-­‐G,	  investigational	  arm)	  or	  gemcitabine	  alone	  (G,	  comparator	  arm).	  
The	  analysis	  was	  conducted	  using	  established	  methodology[3]	  to	  identify	  significant	  differences	  in	  primary	  
(overall	  survival	  -­‐	  OS)	  and	  secondary	  outcomes	  (progression-­‐free	  survival	  –	  PFS	  –	  and	  overall	  response	  rate	  
–	  ORR)	  between	  investigational	  and	  comparator	  arms.	  Relative	  risk	  (RR)	  was	  chosen	  as	  measure	  parameter	  
instead	   of	   Peto’s	   odds	   ratio	   in	   order	   to	   decrease	   the	   risk	   of	   overestimation[12].	   Six	   phase	   III	   trials	  were	  
selected,	  accounting	  for	  3,463	  patients.	  A	  sensitivity	  analysis	  according	  to	  the	  specific	  molecular	  pathway	  
targeted	  by	  the	  agent	  added	  to	  gemcitabine	  (epidermal	  growth	  factor	  receptor	  –	  EGFR,	  farnesyl	  transferase	  
-­‐	   FT,	  matrix	  metalloproteases	  –	  MMP,	  and	  vascular	  endothelial	   growth	   factor	  –	  VEGF)	  was	  conducted,	   in	  
order	  to	  screen	  for	  potentially	  significant	  differential	  effects.	  Overall,	  no	  significant	  OS	  advantage	  for	  TA-­‐G	  
over	  G	  was	  found,	  in	  either	  the	  overall	  or	  the	  sensitivity	  analysis	  (interaction	  p=0.82,	  Figure	  1	  and	  Table	  1);	  
similarly,	  no	  differential	  effects	  of	   the	  pathway	   inhibitors	   tested	  were	   found	   in	   the	  secondary	  end-­‐points	  
(Table	  1).	  	  
Other	  trials	  testing	  novel	  targeted	  agents	  (or	  combination	  thereof)	  in	  addition	  to	  gemcitabine	  not	  matching	  
our	  meta-­‐analysis	  primary	  search	  criteria	  (see	  above)	  have	  been	  reported.	  The	  AViTA	  trial	  [13]	  investigated,	  
in	  a	  randomized	  phase	  III	  setting,	  the	  impact	  of	  double	  VEGF/EGFR	  pathway	  blockade	  (using	  the	  anti-­‐VEGF	  
mAb	  bevacizumab	  and	  the	  EGFR	  tyrosine	  kinase	  inhibitor	  erlotinib)	  in	  addition	  to	  gemcitabine,	  as	  compared	  
to	   the	   standard	   combination	  of	   gemcitabine	  and	  erlotinib,	  which	  had	  previously	   shown	   to	  modestly,	  but	  
significantly,	  prolong	  survival	  over	  gemcitabine	  alone	  [14].	  With	  a	  total	  of	  306	  patients	  randomly	  assigned	  
to	   bevacizumab/erlotinib/gemcitabine	   and	   301	   patients	   assigned	   to	   erlotinib/gemcitabine/placebo,	   the	  
study	  failed	  to	  demonstrate	  a	  significant	  improvement	  in	  OS	  (median	  OS	  7.1	  and	  6.0	  months,	  respectively;	  
hazard	   ratio	   [HR]:	   0.89;	   95%	   CI,	   0.74	   to	   1.07;	   p=0.2087),	   even	   though	   the	   addition	   of	   bevacizumab	   to	  
erlotinib/gemcitabine	  significantly	   improved	  PFS	   (HR:	  0.73;	  95%	  CI,	  0.61	   to	  0.86;	  p=0.0002)	   [15].	  Another	  
agent	   that	   has	  been	   tested	   in	   combination	  with	   gemcitabine	   in	   advanced	  PDAC	   is	   axitinib,	   a	   potent	  oral	  
inhibitor	  of	  VEGF	  receptors	  1,	  2,	  3	  [16].	  Such	  agent	  showed	  promise	  in	  a	  phase	  II	  randomized	  study	  [17]	  in	  
103	  patients	  with	  advanced	  PDAC	  who	  were	  randomly	  assigned	  to	  gemcitabine	  ±	  axitinib	  in	  a	  2:1	  ratio,	  with	  
patients	  on	  the	  axitinib/gemcitabine	  arm	  experiencing	  longer	  median	  OS	  as	  compared	  to	  patients	  receiving	  
gemcitabine	   only	   (6.9	   months,	   95%	   CI	   5.3−10.1	   months,	   versus	   5.6	   months,	   95%	   CI	   3.9−8.8	   months,	  
respectively;	  HR:	  0.71,	  95%	  CI	  0.44−1.13).	  However,	   such	  promising	   results	  did	  not	  hold	  up	   in	  a	  phase	   III	  
trial	  testing	  the	  superiority	  of	  adding	  axitinib	  to	  gemcitabine	  versus	  gemcitabine	  alone	  [18];	  indeed,	  based	  
on	  an	   interim	  analysis	  performed	  after	  630	  patients	  had	  been	  accrued	  and	  223	  deaths	  had	  occurred,	   the	  
Independent	  Data	  Monitoring	  Committee	   found	  no	  evidence	  of	   improvement	   in	   the	  primary	  endpoint	  of	  
OS	   in	   patients	   treated	   with	   axitinib/gemcitabine	   as	   compared	   to	   gemcitabine	   alone	   and	   recommended	  
study	  discontinuation.	  
Analysis	   of	   available	   data	   clearly	   speaks	   to	   the	   failure	   of	   targeted	   agents	   employed	   so	   far	   to	   improve	  
outcomes	  in	  advanced	  PDAC.	  Rather	  than	  fostering	  therapeutic	  nihilism,	  these	  results	  call	   for	  an	   in-­‐depth	  
analysis	   of	   potential	   reasons	   for	   failure.	   The	   first	   reason	   may	   be	   the	   choice	   of	   agents,	   such	   as	   MMP	  
inhibitors,	   that	  are	   largely	   ineffective	  as	   single-­‐agents;	   indeed,	   combined	  analysis	  of	   the	   two	   randomized	  
studies	   head-­‐to-­‐head	   comparing	   MMP	   inhibitors	   with	   gemcitabine	   [19,	   20],	   uniformly	   demonstrates	   a	  
significantly	  worse	  outcome	  for	  patients	  allocated	  to	  experimental	  treatment	  (RR	  for	  OS	  and	  ORR	  1.45,	  95%	  
CI	  1.01-­‐2.10,	  p=0.04,	  and	  0.14,	  95%	  CI	  0.05-­‐0.40,	  p<0.0001,	  respectively).	  Second,	  the	  chosen	  agent	  may	  fail	  
to	  hit	   its	  putative	  target(s);	   this	  appears	  to	  be	  the	  case	  for	  FT	   inhibitors,	  that	  may	  fail	   to	  effectively	  block	  
KRAS	   activity,	   due	   alternative	   activation	   pathways,	   such	   as	   geranyl-­‐geranylation	   [21].	   General	  
methodological	  issues,	  such	  as	  insufficient	  target	  validation,	  inadequate	  phase	  II	  testing,	  and	  a	  rush	  to	  bring	  
new	   compounds	   into	   phase	   III	   trials	   [22,	   23],	   may	   also	   have	   contributed	   to	   the	   general	   failure	   of	   new	  
approaches	  to	  impact	  on	  survival	  of	  PDAC	  patients.	  	  
	  
Hints	  from	  genetics	  of	  hereditary	  forms	  and	  molecular	  risk	  factors.	  
In	  contrast	   to	  other	  malignancies,	  such	  as	  kidney	  cancer	  [24,	  25],	   for	  which	  genetic/molecular	  analysis	  of	  
hereditary	  forms	  has	  provided	  useful	   insights	  into	  the	  pathogenetic	  mechanisms	  of	  sporadic	  cases	  as	  well	  
as	  an	  indication	  of	  molecular	  targets	  to	  be	  pursued	  for	  therapy,	  familial	  cancer	  syndromes	  with	  increased	  
risk	  of	  developing	  pancreatic	  cancer	  shed	   little	   light	  on	  molecular	  mechanisms	  of	  PDAC	  development	  and	  
provide	   little	   guidance	   for	   selecting	   novel	   targets	   for	   therapy	   (Table	   2)	   [26,	   27].	   In	   approximately	   8%	   of	  
cases	   PDAC	   occurs	   in	   patients	   with	   a	   family	   history	   of	   pancreatic	   cancer	   (i.e.	   at	   least	   two	   first-­‐degree	  
relatives	  affected	  by	  the	  disease),	  the	  genetic/environmental	  causes	  of	  which	  remain	  unknown	  in	  most	  of	  
the	  cases;	  however,	  some	  cases	  of	  familial	  pancreatic	  cancer	  arise	  in	  a	  well-­‐defined,	  genetically	  determined	  
cancer	  predisposition	   syndrome.	  Almost	   all	   of	   these	   syndromes	   are	   linked	   to	   the	   failure	  of	  DNA	  damage	  
repair	   or	   cell-­‐cycle	   control	   mechanisms,	   functions	   that	   are	   required	   by	   all	   cells,	   resulting	   in	   increased	  
lifetime	   risk	   of	  many	   different	   cancers,	  without	   any	   specificity	   for	   PDAC	   (Table	   2)	   [26,	   27].	   One	   notable	  
exception	   is	   the	  hereditary	  pancreatitis	   syndrome	   characterized	  by	   recurrent	  attacks	  of	  pancreatitis	  with	  
typical	   childhood	   onset	   and	   long-­‐term	   exocrine	   and	   endocrine	   failure;	   approximately	   80%	   of	   cases	   of	  
hereditary	  pancreatitis	  are	  caused	  by	  mutations	   in	   the	  cationic	   trypsinogen	   (PRSS1)	  gene,	   inherited	   in	  an	  
autosomal	  dominant	  fashion,	  and	  carry	  a	  specifically	  increased	  lifetime	  risk	  for	  pancreatic	  cancer	  (up	  to	  53-­‐
fold).	  This	  risk	   is	  correlated	  with	  the	  duration	  and	  severity	  of	  pancreatitis	  attacks,	  with	  those	  having	  early	  
onset	  of	  pancreatitis	  and	   long-­‐term	  progression	  to	  diabetes	  being	  at	  greatest	  risk;	   in	  addition,	  genetically	  
determined	   risk	  may	  also	   interact	  with	  environmental	   factors,	   as	   smokers	  with	  PRSS1	  mutations	   tend	   to	  
develop	   cancer	   20	   years	   prior	   to	   non-­‐smokers	   [26,	   27].	   This	   situation	   actually	   recapitulates	   the	   known	  
relationship	  between	  environmental	  risk	  factors	  (alcohol	  intake,	  smoking	  habit),	  pancreas-­‐directed	  chronic	  
inflammation	   (chronic	   pancreatitis),	   and	   pancreatic	   carcinogenesis	   as	   it	   is	   observed	   epidemiologically	   in	  
sporadic	   cases	   of	   PDAC	   [28,	   27]	   and	   may	   yield	   novel	   targets	   for	   PDAC	   therapy,	   particularly	   along	  
inflammatory	   pathways	   such	   as	   cyclooxygenase-­‐2	   (COX-­‐2),	   peroxisome	   proliferator-­‐activated	   receptor	   γ	  
(PPARγ),	  and	  nuclear	  factor	  κB	  (NF-­‐κB,	  reviewed	  elsewhere	  in	  this	  issue)	  [29].	  Another	  interesting	  genetic	  
link	   between	   chronic	   pancreatitis	   and	   the	  development	  of	   PDAC	   is	   provided	  by	  mutations	   in	   the	   SPINK1	  
gene,	  which	  may	  be	   inherited	  and	  amplify	  the	  risk	  of	  pancreatitis	  due	  to	  environmental	  alcohol	  exposure	  
and	   have	   recently	   been	   shown	   to	   occur	   in	   a	   high	   proportion	   of	   cases	   of	   PDAC	   developing	   in	   a	   chronic	  
pancreatitis	  background	  and,	  at	  much	  lower	  frequency,	  in	  sporadic	  PDAC	  cases	  [28,	  26,	  30].	  
Finally,	   insights	  into	  putative	  novel	  targets	  for	  therapeutic	   intervention	  in	  PDAC	  come	  from	  the	  molecular	  
dissection	   of	   the	   epidemiological/clinical	   relationships	   between	   obesity,	   diabetes,	   and	   pancreatic	   cancer	  
(recently	   reviewed	   in	   ref.	   [31]).	   Both	   obesity	   [32,	   33,	   34]	   and	   diabetes	   [35,	   36,	   37]	   are	   established	   risk	  
factors	  for	  pancreatic	  cancer	  and	  obesity	  may	  also	  impact	  on	  PDAC-­‐specific	  survival	  [34,	  31].	  Although	  the	  
molecular	  mechanisms	  underlying	  such	  epidemiological	  associations	  remain	  to	  be	  established,	  an	  emerging	  
view	   links	   obesity	   and	   diabetes	   to	   PDAC	   development	   and	   progression	   through	   a	   complex	   interaction	  
between	   insulin,	   the	   insulin-­‐like	   growth	   factor-­‐1	   (IGF-­‐1)/IGF-­‐1R	   system,	   and	   adipokines	   [31].	   This	   view	   is	  
supported	  by	  recent	  evidence	  from	  genome-­‐wide	  association	  studies	  identifying	  the	  nuclear	  receptor	  5A2	  
(NR5A2)	   gene	   as	   a	   significant	   predisposing	   factor	   for	   PDAC	   [38];	   interestingly	   NR5A2	   has	   also	   been	  
implicated	  in	  the	  development	  of	  diabetes	  and	  is	  associated	  with	  obesity	  through	  its	  transcriptional	  control	  
of	  the	  adiponectin	  gene,	  thus	  providing	  a	  possible	  molecular	  link	  between	  metabolic	  dysfunction	  and	  PDAC	  
development	   [39,	   40].	   Another	   epidemiological	   finding	   that	   might	   open	   the	   way	   to	   novel	   mechanistic	  
insights	  into	  PDAC	  development,	  and	  potentially	  yield	  novel	  therapeutic	  targets,	  is	  the	  association	  between	  
genetic	  variations	  in	  the	  ABO	  blood	  group	  locus	  and	  pancreatic	  cancer	  risk	  [41,	  42],	  which	  may	  be	  explained	  
mechanistically	  by	   the	  contribution	  of	   the	  ABO	  system	  to	   the	  regulation	  of	   inflammation	  and	  thrombosis	  
[31].	  	  	  	  
	  
EMT	  program	  and	  EGFR	  pathway	  in	  pancreatic	  cancer.	  
Increasing	   evidence	   indicates	   that	   cancer	   cells	   are	   subjected	   to	   the	   epithelial-­‐mesenchymal	   transition	  
(EMT),	   a	   process	   by	   which	   epithelial	   cells	   undergo	   remarkable	   morphologic	   changes	   characterized	   by	   a	  
transition	   from	   an	   epithelial	   to	   a	   fibroblastic	   phenotype	   (mesenchymal	   phenotype)	   leading	   to	   increased	  
motility	   and	   invasion	   [43,	   44].	   The	   process	   of	   EMT	   involves	   loss	   of	   epithelial	   cell-­‐cell	   junction,	   actin	  
cytoskeleton	  reorganization,	  and	  up-­‐regulation	  of	  mesenchymal	  molecular	  markers	  such	  as	  fibronectin,	  α-­‐
smooth	   muscle	   actin	   (SMA),	   vimentin,	   and	   N-­‐cadherin.	   The	   zinc	   finger	   Snail	   homologues	   (Snail1,	  
Snail2/Slug,	  and	  Snail3)	  and	  several	  basic	  helix-­‐loop-­‐helix	  factors	  such	  as	  Twist,	  ZEB1,	  ZEB2/SIP1,	  and	  TCF3/	  
E47/E12,	  transcriptionally	  repress	  E-­‐cadherin	  the	  main	  constituent	  of	  adhesion	  junctions.	  Diverse	  upstream	  
signals	  increase	  the	  expression	  of	  these	  E-­‐cadherin	  repressors	  at	  the	  mRNA	  level.	  The	  most	  relevant	  factors	  
are	   the	   transforming	   growth	   factor-­‐beta	   (TGFβ)/bone	   morphogenic	   protein	   (BMP)	   family	   of	   cytokines,	  
released	   from	   cancer-­‐associated	   stromal	   cells	   such	   as	   fibroblasts	   that,	   differently	   from	   their	   normal	  
counterpart,	  secret	  excess	  amounts	  of	  extracellular	  matrix	  (ECM),	  growth	  factors	  and	  chemokines	  [45].	  The	  
acquisition	  of	  EMT-­‐like	  phenotype	  by	  cancer	  cells	  is	  reminiscent	  of	  cancer	  stem-­‐like	  cells.	  Along	  these	  lines,	  
a	  prominent	  role	  for	  ZEB1-­‐mediated	  EMT	  has	  been	  identified	  [46].	  The	  authors	  suggest	  that	  ZEB1	  links	  EMT	  
activation	  and	  stemness	  maintenance,	  by	  suppressing	  stemness-­‐inhibiting	  microRNAs.	  On	  the	  other	  hand	  
the	  silencing	  of	  ZEB1	  not	  only	   induces	  EMT	  reversion,	  but	  also	  increases	  cellular	  sensitivity	  to	  therapeutic	  
agents	  [47].	  This	   is	   in	   line	  with	  the	  concept	  that	  the	  EMT	  program	  is	   linked	  to	  drug	  resistance	  and	  can	  be	  
induced	  in	  cancer	  cells	  by	  stress	  conditions	  such	  as	  exposure	  to	  radiation	  or	  to	  anticancer	  agents	  [48,	  45].	  
Shah	   and	   coauthors	   have	   reported	   that	   gemcitabine-­‐resistant	   pancreatic	   cancer	   cell	   lines	   established	   by	  
continuous	   exposure	   to	   the	   drug,	   can	   undergo	   EMT	   with	   increased	   expression	   of	   Snail	   and	   Twist	   [49],	  
supporting	   the	   idea	   that	   therapeutic	   strategies	   to	   reverse	   EMT	   should	   be	   evaluated,	   considering	   the	  
molecular	  factors	  inducing	  the	  EMT	  process.	  
These	  concepts	  may	  be	  important	  also	  in	  the	  context	  of	  molecularly	  targeted	  therapies,	  particularly	  those	  
directed	  against	  EGFR.	  EGFR	  overexpression	  has	  been	  reported	  in	  pancreatic	  cancer	  [50,	  51]	  and	  up	  to	  60%	  
of	  pancreatic	  surgical	  specimens	  overexpress	  EGFR	  [52].	  Tzeng	  and	  colleagues	  reported	  that	  there	  are	  no	  
EGFR	  mutations	   in	   pancreatic	   cancer	   [53],	  whereas	   alternative	  mechanisms,	   such	   as	   EGFR	  genomic	   gain,	  
aberrant	   ligand	   stimulation,	   receptor	  activation,	   absence	  of	  negative	   regulatory	   feedback	  molecules,	   and	  
activation	  of	  downstream	  adaptor	  proteins	  like	  ERK1/2	  and	  Akt	  support	  pancreatic	  tumor	  dependence	  on	  
EGFR	  signaling.	  However,	  clinical	  results	  with	  both	  anti-­‐EGFR	  mAbs	  and	  small-­‐molecule	  TKI	  have	  been	  less	  
than	   optimal	   (see	   Figure	   and	   Table	   1).	   Mechanisms	   aside	   from	   mutation	   of	   the	   EGFR	   tyrosine	   kinase	  
domain	  must	  therefore	  dictate	  drug	  sensitivity.	   In	  vitro	  and	   in	  vivo	  studies	  demonstrated	  that	  EMT	  status	  
may	   be	   an	   indicator	   of	   sensitivity	   to	   EGFR	   inhibitors	   [54]:	   cell	   lines	   classified	   as	   sensitive	   expressed	   the	  
canonical	  epithelial	  marker	  E-­‐cadherin	  and	  displayed	  the	  classic	  cobblestone	  epithelial	  morphology	  and	  the	  
tight	   cell–cell	   junctions	   of	   epithelial	   cells.	   Conversely,	   relatively	   insensitive	   cell	   lines	   lacked	   epithelial	  
markers	   and	   expressed	   proteins	   characteristic	   of	  mesenchymal	   cells,	   including	   vimentin,	   fibronectin	   and	  
ZEB-­‐1	   and	   exhibited	   a	   more	   fibroblastic,	   scattered	   morphology.	   Among	   the	   events	   leading	   to	   EMT,	   the	  
disassembly	  of	  adherens	  junctions	  and	  the	  acquisition	  of	  a	  more	  motile	  and	  invasive	  phenotype	  through	  a	  
significant	  reorganization	  of	  the	  actin	  cytoskeleton,	  play	  a	  crucial	  role.	  Human	  Mena	  (hMena)	  is	  a	  member	  
of	  the	  enabled/vasodilator-­‐stimulated	  phosphoprotein	  (Ena/VASP)	  family,	  key	  actin	  cytoskeleton	  regulatory	  
molecules	   controlling	   cell	   shape,	   movement,	   and	   actin	   organization	   at	   cadherin	   adhesion	   contacts.	  
Experimental	  data	  suggest	  that	  hMena	  couples	  tyrosine	  kinase	  signalling	  to	  the	  actin	  cytoskeleton.	  Pino	  et	  
al.	   showed	   that	   the	   expression	   of	   hMena,	   and	   particularly	   of	   its	   epithelial	   specific	   splice	   variant	   isoform	  
hMena¹¹ª	   [55],	  was	   restricted	   to	   the	   cancer	   cell	   lines	   that	  were	   E-­‐cadherin	   positive	   and	   negative	   for	   the	  
expression	  of	  vimentin	  and	  N-­‐cadherin	  demonstrating	  that	  hMena¹¹ª	  is	  a	  marker	  of	  an	  epithelial	  phenotype	  
in	  pancreatic	  cancer	  cell	   lines	  [56].	  Moreover,	  the	  expression	  of	  hMena/	  hMena¹¹ª	   is	  predictive	  of	   in	  vitro	  
response	   to	   erlotinib,	   thus	   strongly	   supporting	   prospective	   studies	   to	   assess	   whether	   this	   molecular	  
signature	  may	   be	   associated	  with	   an	   improved	   clinical	   response	   to	   EGFR	   targeted	   therapy	   in	   pancreatic	  
cancer.	  
	  
Novel	  molecular	  targets:	  Apoptotic	  pathways.	  
Programmed	   cell	   death	   or	   apoptosis	   is	   a	   critical	   process	   that	  maintains	   normal	   tissue	   homeostasis.	   Two	  
crosstalking	   pathways	   regulate	   apoptosis	   and	   both	   ultimately	   trigger	   caspase	   activity:	   	   in	   the	   intrinsic	  
pathway,	  mithocondria	  play	  a	  key	  role	  and	  the	  apoptotic	  process	  occurs	  for	  an	  imbalance	  between	  pro-­‐	  and	  
anti-­‐apoptotic	  members	  of	  the	  Bcl-­‐2	  family	  of	  proteins;	  the	  extrinsic	  pathway	  is	  activated	  by	  the	  interaction	  
between	   soluble	   or	  membrane-­‐bound	  death-­‐inducing	   ligands	   and	   death	   receptors	   of	   the	   tumor-­‐necrosis	  
factor	  receptor	  (TNFR)	  superfamily,	  including	  TNFR,	  FAS	  and	  TRAIL	  (TNF-­‐related	  apoptosis	  inducing	  ligand)	  
receptors	  on	  the	  cell	  surface	  [57].	  	  
Resistance	  towards	  apoptosis	  is	  a	  hallmark	  of	  pancreatic	  cancer	  [57].	  In	  PanIN	  1	  and	  2	  lesions,	  no	  apoptotic	  
cells	   could	   be	   detected,	   arguing	   for	   the	   contribution	   of	   anti-­‐apoptotic	   mechanisms	   early	   in	   the	  
carcinogenesis	   of	   PDAC	   [58].	   Studies	   in	   pancreatic	   cancer	   have	   described	   multiple	   defects	   in	   apoptosis	  
signaling	   at	   different	   levels	   of	   the	   pathway.	   Deregulated	   expression	   of	   apoptosis-­‐regulating	   molecules,	  
including	  members	  of	  the	  Bcl-­‐2	  family,	  such	  as	  Bcl-­‐2,	  Bcl-­‐XL,	  Bax,	  and	  Bak,	  is	  a	  common	  feature	  in	  PDAC.	  It	  
has	   been	   shown	   that	   acquired	   resistance	   of	   pancreatic	   cancer	   cell	   lines	   to	   5-­‐FU	   and	   gemcitabine	   is	  
associated	  with	  an	  alteration	  in	  the	  Bax/Bcl-­‐xL	  ratio	   in	  favor	  of	  the	  activation	  of	  antiapoptotic	  genes	  [59].	  
Dong	  et	  al.	  demonstrated	  upregulation	  of	  Bcl-­‐2	  and	  decreased	  Bax	  expressions	   in	  micro-­‐RNA-­‐21	  (miR-­‐21)	  
mimic-­‐transfected	   cells.	   The	   increased	   expression	   of	   Bcl-­‐2	   was	   accompanied	   by	   less	   apoptosis,	   lower	  
caspase-­‐3	   activity	   and	  decreased	   chemosensitivity	   to	   gemcitabine,	   compared	  with	   negative	   control	   cells.	  
Opposite	  trends	  were	  found	  in	  the	  cells	  transfected	  with	  miR-­‐21	  inhibitor[60].	  	  Furthermore	  expression	  of	  
the	   proapoptotic	   Bax	   gene	   in	   tumor	   samples	   from	   patients	   with	   PDAC	   is	   a	   strong	   indicator	   of	   a	   longer	  
survival	  and	  overexpression	  of	  Bax	  may	  sensitize	  pancreatic	  cancer	  cells	  to	  5-­‐FU	  and	  gemcitabine	  [61].	  Bcl-­‐
xL	  also	  plays	  a	   role	   in	  protecting	  PDAC	  cells	   from	  FAS	  and	  TRAIL-­‐mediated	  apoptosis	  and	   is	  constitutively	  
overexpressed	   in	   pancreatic	   cancer	   cell	   lines	   highly	   resistant	   to	   Fas	   and	   TRAIL-­‐mediated	   apoptosis	   [59].	  
While	  overexpression	  of	  Bcl-­‐xL	  in	  cell	   lines	  with	  endogenously	  low	  levels	  induces	  complete	  suppression	  of	  
apoptosis,	  inhibition	  of	  Bcl-­‐xL	  function	  by	  either	  antisense	  oligonucleotides	  or	  Bax	  overexpression	  results	  in	  
sensitization	   of	   cells	   with	   high	   levels	   of	   Bcl-­‐xL,	   such	   as	   Panc-­‐1	   or	   Panc-­‐TuI,	   resulting	   in	   the	   inhibition	   of	  
pancreatic	  cancer	  cell	  growth,	  induction	  of	  apoptosis,	  and	  increased	  sensitivity	  to	  chemotherapeutic	  agents	  
like	  gemcitabine	  [59].	  BNIP3	  is	  a	  hypoxia-­‐inducible	  mithocondrial	  member,	  belonging	  to	  the	  BH3	  subfamily	  
of	  Bcl2	  family	  proteins,	  which	  antagonizes	  the	  activity	  of	  prosurvival	  proteins	  such	  as	  Bcl-­‐2	  and	  Bcl-­‐xL	  [62].	  
Under	   physiologic	   conditions	   BNIP3	   is	   usually	   undetectable	   in	  most	   tissue	  while	   it	   has	   been	   reported	   in	  
hypoxic	   regions.	   Despite	   the	   characteristic	   hypoxic	   milieu	   of	   the	   pancreatic	   cancer	   (see	   below),	   several	  
studies	  show	  that	  BNIP3	  expression	  levels	  in	  PDAC	  cell	  lines	  and	  tissue	  samples	  are	  low,	  as	  compared	  to	  the	  
normal	   pancreas,	   possibly	   due	   to	   hypermethylation	   of	   the	   BNIP3	   promoter	   [62].	   Recently	   Erkan	   et	   al.	  
demonstrated	   alterations	   of	   BNIP3	   expression	   during	   transformation,	   although	   the	   major	   loss	   of	   the	  
protein	   occurs	   in	   later	   stages	   of	   PDAC	   development	   and	   correlates	  with	   poorer	  median	   survival	   [61].	   In	  
addition,	   downregulation	  of	  BNIP3	   results	   in	   increased	   resistance	   to	  5-­‐fluorouracil	   and	  gemcitabine	   [63],	  
although	  the	   latter	  point	   is	  more	  controversial	   [62];	  regardless,	  BNIP3	  expression	  may	  have	  an	   impact	  on	  
prediction	  of	  prognosis	  of	  patients	  with	  pancreatic	  cancer	  [62].	  
Human	  pancreatic	  cancer	  tumors	  or	  cell	  lines	  exhibit	  heterogeneous	  responses	  to	  TRAIL,	  and	  some	  of	  them	  
are	   intrinsically	   resistant	   to	   TRAIL-­‐induced	   apoptosis	   [64],	   such	   as	   human	   pancreatic	   cancer	   cell	   lines	  
harboring	   codon	   12	   mutations of	   the	   K-­‐Ras	   gene	   [65,	   66].	   	   Recent	   experimental	   data	   showed	   that	   the	  
histone	   deacetylase	   inhibitor	   LBH589	   is	   able	   to	   promote	   ubiquitin/proteasome-­‐mediated	   degradation	   of	  
the	  TRAIL	  inhibitor	  c-­‐FLIP,	  thereby	  sensitizing	  PDAC	  cells	  to	  TRAIL-­‐induced	  apoptosis	  [67,	  68,	  69].	  	  
Similarly,	   it	  has	  been	  reported	  that	  treatment	  with	  cycloheximide,	  a	  compound	  able	  to	  suppress	  FLIP	  and	  
TRAIL	  expression,	  may	  enhance	  and	  restore	  apoptosis	  in	  TRAIL-­‐resistant	  cells	  [70].	  Mori	  et	  al.	  reestablished	  
TRAIL-­‐induced	   apoptosis	   in	   TRAIL-­‐resistant	   cells	   by	   exposure	   to	   FLIP	   antisense;	   moreover,	   the	   effect	   of	  
TRAIL	   was	   enhanced	   by	   the	   combination	   of	   FLIP	   antisense	   and	   embelin,	   a	   small	   inhibitor	   of	   X-­‐linked	  
inhibitor	  of	  apoptosis	  protein	  (XIAP)	  [71].	  Other	  data	  support	  the	  increase	  of	  the	  apoptosis-­‐sensitization	  of	  
TRAIL-­‐resistant	  pancreatic	  carcinoma	  cells	  by	  down-­‐regulation	  of	  c-­‐FLIP	  and	  XIAP[72,	  73,	  74,	  75].	  TRAIL	  has	  
a	  great	  potential	  for	  clinical	  application	  and	  agonistic	  TRAIL	  receptors	  (TRAIL-­‐R1/R2)	  are	  being	  investigated	  
as	  therapeutic	  targets.	  The	  agonistic	  antibody	  to	  the	  proapoptotic	  TRAIL	  receptor	  TRAIL-­‐R,	  Mapatumumab,	  
has	  been	  showed	  to	  	  reduce	  viability	  in	  pancreatic	  carcinoma	  cells	  and	  to	  cooperate	  with	  XIAP	  inhibitor	  to	  
trigger	  caspase	  activation	  in	  in	  vivo	  tumor	  models	  [76],	  and	  is	  currently	  being	  tested	  in	  clinical	  trials.	  
The	   therapeutic	  potential	  of	  XIAP	   inhibition	   in	  PDAC,	   is	  highlighted	  by	  evidence	   that	   small-­‐molecule	  XIAP	  
inhibitors	   synergize	  with	   TRAIL	   to	   induce	   apoptosis	   and	   inhibit	   survival	   of	   PDAC	   cells	   in	   vitro	   and	   act	   in	  
concert	   with	   TRAIL	   to	   suppress	   the	   growth	   of	   established	   pancreatic	   cancer	   in	   vivo	   [77].	   Karikari	   et	   al.	  
showed	  that	  XAntag,	  a	  functional	  inhibitor	  able	  to	  disrupt	  the	  interaction	  of	  XIAP	  with	  caspases,	  is	  capable	  
of	   activating	  downstream	  caspases	   in	  pancreatic	   cancer	   cells	   and	  of	   inhibiting	  pancreatic	   growth	   in	   vivo.	  
XAntag	  also	   showed	  synergy	  when	  combined	  with	  proapoptotic	   ligands	   (TRAIL)	  and	  sensitized	  pancreatic	  
cancer	  cells	  to	  common	  pancreatic	  cancer	  therapy,	  such	  as	  radiation	  and	  gemcitabine	  [78].	   In	  addition	  to	  
XIAP,	   data	   report	   that	   two	  other	  members	   of	   the	   inhibitors	   of	   apoptosis	   (IAP)	   protein	   family,	   cIAP2	   and	  
survivin	  are	  overexpressed	  during	  carcinogenesis	  of	  PDAC.	  Early	  overexpression	  of	  cIAP2	  was	  demonstrated	  
in	  30%	  of	  low-­‐grade	  PanIN	  lesions,	  50%	  of	  high-­‐grade	  PanIN	  lesions	  and	  85%	  of	  PDAC	  [57].	  Survivin	  is	  also	  
often	  overexpressed	  in	  pancreatic	  cancer,	  where	  it	  participates	  in	  the	  development	  and	  progression	  of	  the	  
disease	  and	  correlates	  with	  poor	  prognosis	  [79].	  	  Guan	  et	  al.	  investigated	  the	  effects	  of	  a	  small	  interfering	  
RNA	  (siRNA)	  directed	  against	  survivin,	  showing	  that	  it	  inhibits	  surviving	  expression	  in	  pancreatic	  cancer	  cell	  
lines,	  induces	  apoptosis,	  and	  enhances	  radiosensitivity	  [80].	  	  	  
	  
Novel	  molecular	  targets:	  HIF	  and	  angiogenesis.	  
The	  hypoxia	  inducible	  factor	  (HIF)	  family	  of	  transcription	  factors	  plays	  a	  crucial	  role	  in	  response	  to	  hypoxia-­‐
specific	  stress	  and	  is	   involved	  in	  resistance	  to	  oxidative	  stress,	  protecting	  the	  cancer	  cell	  against	  cytotoxic	  
therapy	  and	  inversely	  correlating	  with	  sensitivity	  to	  ionizing	  radiation.	  HIF-­‐1	  is	  a	  heterodimer	  composed	  of	  
α	   and	   β	   subunits.	  While	   HIF-­‐1β	   is	   constitutively	   expressed,	   HIF-­‐1α	   is	   regulated	   in	   an	   oxygen-­‐dependent	  
manner	   at	   the	  post-­‐translational	   level	   and	   is	   undetectable	  under	  normoxic	   conditions.	  Hypoxia	   stabilizes	  
HIF-­‐1α,	  which	   then	   translocates	   to	   the	   nucleus,	   dimerizes	  with	  HIF-­‐1β	   and	   activates	   the	   transcription	   of	  
hypoxia-­‐regulated	   genes	   [81].	   Several	   studies	   showed	   that	  HIF-­‐1α	  positive	   cells	   are	  mostly	   localized	   at	   a	  
tumor's	   infiltrating	   margin,	   around	   the	   periphery	   of	   necrotic	   areas,	   and	   surround	   regions	   of	   high	  
microvessel	   density	   .	  HIF-­‐1	  overexpression	  may	   represent	   an	  early	   event	   in	   carcinogenesis	   and	   seems	   to	  
play	  an	  important	  role	  also	  in	  cancer	  growth	  and	  metastasis	  [82].	  	  
The	  overexpression	  of	  HIF-­‐1α	  has	  been	  demonstrated	  in	  multiple	  types	  of	  human	  cancer,	  as	  well	  as	  in	  their	  
regional	  and	  distant	  metastases,	  as	  a	  result	  of	  adaptation	  of	  tumor	  cells	  to	  hypoxia.	  HIF-­‐1	  overexpression,	  
in	  turn,	  is	  related	  to	  the	  up-­‐regulation	  of	  proangiogenic	  cytokines	  such	  as	  VEGF	  and	  platelet-­‐derived	  growth	  
factor	  (PDGF),	  which	  confer	  radiation	  resistance	  to	  endothelial	  cells	  as	  well	  as	  increase	  the	  proliferation	  of	  
tumor	  blood	  vessels	   [83,	  84].	  Furthermore,	  HIF-­‐	  1	  transactivates	  various	  hypoxia-­‐responsive	  genes,	  which	  
confer	  malignant	  properties	  to	  tumors	  such	  as	  apoptosis	  resistance,	  enhanced	  tumor	  growth,	  invasion	  and	  
metastasis	   [85].	  Overexpression	  of	  HIF-­‐1α	   and	   its	   role	   in	  angiogenesis	  and	  progression	   is	  associated	  with	  
unfavorable	  prognosis	  and	  poor	  overall	  and	  disease	  free	  survival	  in	  several	  cancers	  [83],	  including	  PDAC,	  in	  
which	  HIF-­‐1	  activation	   in	   response	   to	   low	  oxygen	   levels	  has	  been	  demonstrated	  both	   in	  vitro	   and	   in	  vivo	  
[82].	  Recently,	  Sun	  et	  al.	  and	  Tao	  et	  al.	  showed	  that	  HIF-­‐1α	  expression	  not	  only	  has	  a	  strong	  impact	  on	  the	  
prognosis	  of	  PDAC	  patients,	  but	   is	  also	  correlated	  with	  decreased	  apoptotic	   index,	   increased	  intratumoral	  
microvessel	  density	  and	  VEGF	  expression	  [86,	  87].	  It	  has	  be	  further	  investigated	  to	  what	  extent	  HIF-­‐1α	  and	  
PDGF-­‐A	   are	   coexpressed	   in	   pancreatic	   cancer	   [88].	   Recent	   data	   show	   a	   correlation	   between	   hypoxic	  
environment,	   induced	   HIF-­‐1α	   expression	   and	   pancreatic	   cancer	   cells	   resistance	   to	   gemcitabine	   [89];	  
furthermore	  HIF-­‐1α	   overexpression	   seems	   promote	   EMT	   and	   facilitate	   invasiveness	   of	   pancreatic	   cancer	  
cells	  [90,	  91].	  	  
Targeting	  HIF-­‐1	   is	  a	  possible	  therapeutic	  strategy.	   Inhibition	  of	  HIF-­‐1	  by	  PX-­‐478	   in	  cancer	  cell	   lines	   is	  able	  
not	  only	  to	  reduce	  HIF-­‐1	  protein	  levels	  and	  signaling	  but	  also	  to	  provide	  direct	  radiosensitization	  of	  hypoxic	  
cancer	  cells	  and	   improvement	   in	  direct	   tumor	  cell	   killing	   [92].	  Chen	  et	  al.	   showed	  that	   siRNA	  may	   inhibit	  
HIF-­‐1	  and	  VEGF	  expression	   inducing	  apoptosis	  of	  pancreatic	   cancer	  cells	   through	  NF-­‐κB-­‐independent	  or	   -­‐
dependent	  pathways	  under	  hypoxic	  conditions	  and	  might	  inhibit	  the	  growth	  of	  nude	  mice	  xenografts	  and	  
their	  microvessel	  density	  (MVD)	  [93].	  
	  
	  Novel	  molecular	  targets:	  Developmental	  pathways.	  
The	  hedgehog	  pathway	  
The	  hedgehog	  (Hh)	  pathway	  plays	  an	  important	  role	  during	  embryonic	  development,	  although	  it	  is	  usually	  
inactive	  in	  mature	  organs.	  Hedgehog	  belongs	  to	  a	  family	  of	  secreted	  signaling	  proteins	  comprised	  of	  sonic,	  
indian,	  and	  desert	  hedgehog	  (SHh,	  IHh,	  and	  DHh,	  respectively).	  It	  functions	  by	  binding	  to	  a	  transmembrane	  
protein	  called	  patched	  (Ptch),	  a	  tumor	  suppressor	  protein	  that	  negatively	  regulates	  the	  Hh	  pathway.	  When	  
Hh	  ligands	  bind	  to	  their	  receptors,	  Ptch	  releases	  its	   inhibitory	  protein	  smoothened	  (Smo),	  which	  activates	  
the	  downstream	  effectors	  and	  determines	  the	  nuclear	  localization	  of	  the	  Gli	  transcriptional	  regulators	  with	  
upregulation	  of	  target	  genes	  [94].	  
Aberrant	  activation	  of	  the	  Hh	  pathway	  by	  loss	  of	  Ptch,	  mutation	  in	  Smo	  and	  overexpression	  of	  Gli	  and	  Hh	  
proteins,	  have	  been	   linked	  to	  tumorigenesis	   in	  several	  cancers.	  Pancreatic	  cancer,	   in	  particular,	  shows	  an	  
aberrant	  expression	  of	  SHh	  secreted	  in	  an	  autocrine/paracrine	  manner	  [10].	  SHh	  pathway	  plays	  a	  key	  role	  
in	   the	   growth	   of	   pancreatic	   cancer	   cells	   and	   seems	   to	   be	   implicated	   in	   initiation	   and	   maintenance	   of	  
pancreatic	  ductal	  cancers.	  SHh	  is	  aberrantly	  expressed	  in	  the	  precursor	  lesions	  of	  invasive	  adenocarcinoma,	  
such	   as	   PanIN	   and	   intraductal	   papillary	  mucinous	   neoplasia,	   and	   its	   levels	   increase	   progressively	   as	   the	  
lesions	  progress	   to	  more	  advanced	  stages	   [95].	   Some	  of	   the	  genes	   related	   to	   the	  Hh	  pathway	  are	   tumor	  
suppressors	  or	  oncogenes,	  several	  Hh-­‐target	  genes	  are	  overexpressed	  and	  there	  is	  a	  considerable	  degree	  of	  
cross-­‐talk	  between	  Hh	  and	  other	  oncogenic/oncosuppressor	  pathways,	  including	  the	  MAPK/ERK,	  PI3K/Akt,	  
Wnt,	  and	  TGFβ/BMP	  pathways	  [96].	  For	  example,	  RAS	  and	  Hh	  cooperate	  during	  carcinogenesis,	   initiation,	  
and	   maintenance	   in	   the	   pancreas	   and	   other	   organs.	   Lauth	   et	   al.	   found	   that	   mutant	   RAS	   induces	   and	  
enhances	   SHh	   expression,	   favoring	   paracrine	  Hh	   signaling,	  whereas	   antagonizes	   autocrine	  Hh	   signal	   [97,	  
98].	   SHh	   has	   been	   also	   linked	   to	   cell	   survival	   and	   apoptosis.	  Morton	   at	   al.	   showed	   that	   SHh	   expression	  
protects	   pancreatic	   cancers	   form	   caspase	   8-­‐	   and	   caspase	   3-­‐dependent	   apoptosis,	   in	   part	   through	  
stabilization	   of	   the	   anti-­‐apoptotic	   proteins	   Bcl-­‐2	   and	   Bcl-­‐xL	   [97].	   Other	   data	   have	   shown	   that	   SHh	   can	  
rescue	  cells	  from	  apoptosis	  mediated	  by	  the	  FAS	  death	  receptor,	  allowing	  protection	  from	  tumor-­‐reactive	  
immune	   cells	   [97]	   and	   that	   Hh	   signaling	   plays	   a	   role	   in	   pancreatic	   cancer	   stem	   cells,	   driving	   their	   self-­‐
renewal	  ability	  [99,	  100].	  Finally	  several	  data	  have	  shown	  that	  a	  ligand	  dependent	  activation	  of	  SHh	  occurs	  
in	   the	   tumor	  stromal	  microenvironment	  where	   it	   is	   involved	   in	  myofibroblast	  differentiation	  and	   induces	  
desmoplasia.	  Moreover,	  a	  hypoxia-­‐driven	  upregulation	  SHh,	  Smo	  and	  Gli	  transcription	  and	  a	  SHh	  paracrine	  
loop,	   through	   induction	  of	   stroma-­‐derived	  growth	   factors,	  have	  been demonstrated	   [101,	  102,	  103,	  104,	  
105].	  
All	   these	   evidences	   raised	   interest	   in	   targeting	   this	   pathway	   for	   the	   treatment	   of	   cancer.	   Several	   small	  
molecule	  inhibitors	  are	  being	  evaluated	  in	  clinical	  trials,	  either	  as	  a	  therapy	  directed	  against	  tumor	  cells,	  or	  
as	   a	   strategy	   against	   non-­‐malignant	   stromal	   cells	   that	   support	   the	   growth	   of	   the	   tumor	   [99,	   106].	  
Cyclopamine,	  a	  natural	  steroid	  alkaloid	  antagonist	  of	  Smo,	  has	  been	  shown	  to	  inhibit	  the	  growth	  of	  murine	  
cancer	   cell	   lines,	   downregulate	   the	  HH	   target	   genes	  Gli1	   and	  Ptch,	   selectively	   deplete	   the	  ALDH-­‐positive	  
subpopulation	  of	  PDAC	   stem	  cells,	   impair	   invasive	   capacity,	   prevent	  metastasis,	   and	   significantly	  prolong	  
survival	   in	  murine	  orthotopic	   xenograft	  models	  or	   transgenic	  mouse	  models	  of	  human	  pancreatic	   cancer	  
[107,	  108].	  It	  has	  also	  been	  shown	  that	  tumor	  vasculature	  is	  a	  target	  of	  Hh	  blockade.	  Cyclopamine	  is	  able	  to	  
attenuate	  Hh	  signaling	  in	  the	  stroma,	  determining	  regression	  of	  the	  tumor	  vasculature	  and	  attenuating	  the	  
recruitment	   of	   bone	   marrow	   (BM)-­‐derived	   cells	   [96].	   Olive	   et	   al.	   showed	   that	   IPI-­‐926,	   another	   small-­‐
molecule	   inhibitor	   of	   SMO	   reduce	   the	   dense	   stromal	   reaction	   that	   characterizes	   pancreatic	   cancers	   and	  
transiently	  increases	  tumor	  neovascularization,	  thereby	  facilitating	  drug	  delivery	  and	  increasing	  the	  survival	  
of	   mice	   in	   an	   otherwise	   gemcitabine-­‐resistant	   mouse	   model	   [106,	   109].	   Furthermore	   GDC-­‐0449	  
(Vismodegib),	   a	   Smo	   inhibitor	  with	  a	  high	  degree	  of	   selectivity	   for	   SHH-­‐Gli	   signaling	  has	  been	   showed	   to	  
induce	   significant	   cell	   death	   in	   three	   pancreatic	   cancer	   cell	   lines	   (AsPC-­‐1,	   PANC-­‐1	   and	  MIA	   PaCa-­‐2)	   and	  
pancreatic cancer	  stem	  cells	  (CSCs)	  by	  decreasing	  SHh	  signaling	  components	  (Gli1,	  Gli2,	  Patched-­‐1,	  Patched-­‐
2,	  SHH	  and	  Smo)	  expression,	  Gli-­‐DNA	  binding	  and	  Gli-­‐luciferase	  reporter	  activities.	   In	  addition,	  GDC-­‐0449	  
increased	   the	   expression	   of	   TRAIL-­‐R1/DR4	   and	   TRAIL-­‐R2/DR5,	   decreased	   Bcl-­‐2	   expression,	   and	   induced	  
caspase-­‐3	  activity	  [110].	  	  
	  The	  Notch	  pathway	  
The	   developmental	   signaling	   pathway	   Notch	   plays	   a	   fundamental	   role	   in	   cell	   fate	   decisions	   during	  
embryogenesis	   and	   is	   important	   for	   the	   process	   of	   apoptosis,	   differentiation	   and	   invasion	   [100].	   During	  
pancreatic	  development,	  Notch	  signaling	  maintains	  pancreatic	  epithelial	  cells	  in	  a	  progenitor	  state,	  avoiding	  
the	   premature	   differentiation	   of	   pancreatic	   progenitors	   [111,	   112].	   In	   adult	   tissues,	   Notch	   prevents	   cell	  
terminal	  differentiation	  and	  maintains	   the	  subpopulation	  of	  undifferentiated	  stem/progenitor	   cells	   [113].	  	  
In	  the	  adult	  pancreas,	  under	  normal	  conditions,	  Notch	  is	  relatively	  inactive,	  while	  it	  plays	  an	  important	  role	  
in	  pancreatic	  homeostasis	  and	  actively	  participates	   in	  the	  regeneration	  process	   following	  pancreas	   injury,	  
potentially	   providing	   an	   important	   link	   between	   chronic	   pancreatic	   inflammation	   and	   pancreatic	  
carcinogenesis	   [114].	   The	  Notch	   pathway	   includes	   4	   different	   single-­‐pass	   transmembrane	   receptors.	   The	  
Notch	  signaling	  can	  be	  initiated	  by	  the	  binding	  of	  one	  of	  five	  distinct	  ligands	  (JAGGED-­‐1	  and	  2	  and	  Delta-­‐like	  
(DLL)-­‐1,	   -­‐3,	   and	   -­‐4)	   to	   the	   receptors	   [111].	   The	   receptor-­‐ligand	   interaction	   induces	   the	   proteolytic	  
intramembrane	  cleavage	  of	   the	   receptor	  by	  γ-­‐secretase	  and	   the	   release	  of	  an	  active	   intracellular	  domain	  
(Notch	   intracellular	   domain,	   NICD),	   which	   then	   translocates	   to	   the	   nucleus.	   Here,	   the	   NICD	   induces	   the	  
expression	  of	  a	  series	  of	  target	  genes,	  including	  the	  transcriptional	  repressors	  family	  of	  the	  hairy	  enhancer	  
of	  split	  (Hes)	  and	  Hes-­‐related	  family	  of	  genes	  [112].	  
When	  aberrantly	  regulated,	  Notch	  can	  contribute	  to	  cell	  transformation	  in	  vitro	  and	  to	  the	  development	  of	  
several	  human	  cancers	  [10].	  In	  pancreatic	  cancer,	  the	  Notch	  pathway	  plays	  a	  role	  in	  initiation,	  progression,	  
and	  maintenance	  [112,	  115,	  116].	  Activation	  of	  the	  Notch	  pathway	  has	  been	  observed	  in	  metaplastic	  ductal	  
epithelium,	   in	   early,	   non-­‐invasive	   stages	   of	   disease	   (such	   as	   PanIN),	   and	   in	   PDAC	   tissue	   in	   human	   and	  
mouse	  models	   [112].	  Overexpression	   of	  NICD	   has	   been	   shown	   to	   be	   sufficient	   to	   promote	   acinar-­‐ductal	  
metaplasia	   in	   primary	   acinar	   cell	   culture	   and	   cooperates	   with	   other	   signaling	   pathways	   to	   initiate	  
pancreatic	  carcinogenesis	  [112].	  Moreover,	  Notch	  signaling	  seems	  to	  play	  a	  role	  in	  the	  acquisition	  of	  EMT	  
and	   cancer	   stem-­‐like	   cell	   phenotype	   and	   its	   activation	   has	   been	   shown	   to	   be	   associated	   with	   a	  
chemoresistance	  phenotype	  of	  PDAC	  cells	  [117,	  118].	  No	  somatic	  point	  mutations	  either	  in	  Notch	  genes	  or	  
in	   genes	   encoding	   their	   ligands	   have	   been	   identified.	   Indeed	  mutational	   activation	   of	   Notch	   pathway	   in	  
pancreatic	   cancer	   is	   rare.	   Rather,	   Notch	   activation	   in	   pancreatic	   cancer	   seems	   to	   be	   ligand	   driven.	  
Mullendore	  et	  al	  showed	  an	  endogenous	  overexpression	  of	  Notch	  ligands,	  especially	  of	  JAGGED2	  and	  DLL4,	  
in	  pancreatic	  cancer	  cell	  lines,	  which	  correlated	  with	  induction	  of	  the	  transcriptional	  target	  gene	  Hes	  [111].	  
Notch-­‐1	   has	   been	   reported	   to	   cross-­‐talk	   with	   other	   survival/embryologic	   pathways.	   Several	   data	  
demonstrate	  interactions	  of	  Notch	  with	  RAS,	  in	  both	  development	  and	  tumorigenesis.	  Activated	  KRAS	  and	  
Notch	   signals	   cooperate	   to	   transform	   cells	   and	   to	   initiate	   pancreatic	   carcinogenesis	   and	   Notch	   activity	  
accelerates	   the	   formation	   of	   oncogenic	   KRAS-­‐induced	   PanIN	   lesions	   [10,	   112,	   119].	   Notch-­‐1	   has	   been	  
reported	  to	  crosstalk	  with	  another	  major	  cell	  growth	  and	  apoptotic	  regulatory	  pathway:	  nuclear	  factor-­‐κB	  
(NF-­‐κB).	  Specifically,	  Notch-­‐1	  has	  been	  reported	  to	  strongly	  induce	  NF-­‐κB2	  promoter	  activity	  and	  expression	  
of	  several	  NF-­‐κB	  subunits	  [117].	  
Notch	  is	  a	  potential	  therapeutic	  target	  for	  pancreatic	  cancer	  and	  blocking	  its	  signal	  transduction,	  by	  small-­‐
molecule	   inhibitors,	   showed	   antineoplastic	   effects	   in	   vitro	   and	   in	   vivo.	   	   Wang	   et	   al	   showed	   that	   tumor	  
maintenance	  in	  pancreatic	  cancer	  is	  mostly	  due	  to	  NOTCH1	  activity	  and	  that	  its	  inhibition	  might	  affect	  cell	  
growth	   and	   survival,	   prevent	   invasion	   by	   inhibiting	   NF-­‐κB,	   VEGF	   and	   MMP	   [120].	   Genistein,	   a	   natural	  
isoflavonoid	   found	   in	   soybean	   products,	   and	   curcumin,	   a	   phenolic	   compound	   from	   the	   plant	   Curcuma	  
longa,	  have	  been	  shown	  to	  down-­‐regulate	   the	   transcription	  and	   translation	  of	  Notch-­‐1	  and	  Hes-­‐1	  and	   to	  
inactivate	   NF-­‐κB.	   In	   addition,	   these	   drugs	   induced	   G0-­‐G1	   phase	   cell	   cycle	   arrest,	   with	   reduced	   levels	   of	  
cyclin	  D1,	  and	  induced	  apoptosis	  by	  decreasing	  Bcl-­‐2	  and	  Bcl-­‐xL	  protein	  expression	  [111,	  121].	  Notch	  down-­‐
regulation	   by	   siRNA	   also	   reduces	   VEGF	   expression	   and	   decreases	   MMP-­‐9,	   resulting	   in	   the	   inhibition	   of	  
invasion	  and	  metastasis	  [122].	  A	  different	  therapeutic	  strategy	  is	  the	  prevention	  of	  Notch	  activation	  by	  γ-­‐
secretase	   inhibitors,	  which	   in	   several	   reports	   is	   correlated	   to	   reduced	   proliferation,	   increased	   apoptosis,	  
decreased	  anchorage-­‐independent	  growth	  and	  invasion	  properties	  in	  pancreatic	  cell	  cultures	  [111,123].	  γ-­‐
secretase	  inhibition	  is	  able	  to	  prevent	  acinar-­‐to-­‐ductal	  metaplasia	  in	  vitro,	  suppress	  the	  incidence	  of	  PanIN,	  
and	   block	   the	   progression	   of	   PanIN	   to	   PDAC	   in	   mouse	   models,	   but	   does	   not	   seem	   to	   exert	   a	   strong	  
influence	  during	  more	  advanced	  stages	  of	  PDAC	  progression	  [112].	  
	  
Animal	  models	  of	  PDAC.	  
The	  most	  commonly	  used	  animal	  models	  are	  cell	   line-­‐derived	   tumor	  xenografts	   in	   immunodeficient	  mice	  
[124].	  However,	  this	  approach	  is	  not	  able	  to	  recapitulate	  some	  important	  features	  of	  the	  original	  disease,	  
such	   as	   interaction	   with	   the	   immune	   system,	   stromal	   and	   endothelial	   cells,	   and	   the	   normal	   epithelial	  
environment	   [125,	   126],	   making	   the	   predictive	   value	   of	   therapeutic	   experiments	   conducted	   in	   these	  
models	   at	   least	   questionable,	   particularly	   in	   PDAC	   where	   the	   interaction	   with	   ‘normal’	   stroma	   is	   of	  
paramount	  importance	  [6,	  127].	  	  
As	   an	   alternative	   to	   cell	   line-­‐based	   in	   vivo	  models,	   Hidalgo	   and	   coll.	   have	   developed	   individual	   patient-­‐
derived	   PDAC	   xenotransplantation	   models,	   with	   the	   advantage	   of	   retaining	   the	   genetic	   and	   epigenetic	  
features,	  as	  well	  as	  the	  tumor	  heterogeneity,	  of	  the	  original	  disease	  [128,	  129].	  Although	  this	  approach	  has	  
proven	   feasible	   and	   potentially	   useful	   for	   preclinical/early	   clinical	   drug	   development	   [130],	   it	   still	   lacks	  
substantially	  with	  regard	  to	  the	  role	  of	  tumor-­‐host	  interactions.	  This	  issue	  is	  theoretically	  overcome	  by	  the	  
genetically	  engineered	  mouse	  models	   [131,	  132],	  which	  allow	  modeling	  the	   interplay	  between	  neoplastic	  
cells	  and	  the	  surrounding	  environment,	  providing	  an	  in	  situ	  tumor	  development	  in	  an	  immune-­‐competent	  
model	  [126].	  	  
With	   specific	   regard	   to	   PDAC,	   several	   transgenic	  models	   have	   been	   developed	   [133].	   Among	   these,	   KPC	  
mice	  are	   genetically	   engineered	  models,	  which	   conditionally	   express	   endogenous	  mutant	  K-­‐RAS	  and	  p53	  
alleles	   in	  pancreatic	  cells,	   leading	  to	  the	  development	  of	  pancreatic	  tumors	  [126,	  134].	  PDAC	  in	  KPC	  mice	  
recapitulates	   patho-­‐physiological	   and	  molecular	   features	   of	   human	   PDAC,	   including	   the	   development	   of	  
tumors	  with	  abundant	  stroma	  and	  collagen	  deposition,	  the	  common	  occurrence	  of	  metastasis	  to	  relevant	  
sites,	  cachexia	  and	  activation	  of	  biochemical	  pathways	  and	  genomic	  instability	  [126].	  Recent	  reports	  show	  
that	  K-­‐RAS	  activation	  in	  mouse	  pancreas	  generates	  pancreatic	  intraepithelial	  neoplasia	  (PanIN),	  with	  a	  low	  
frequency	   of	   progression	   to	   invasive	   and	   metastatic	   adenocarcinoma,	   thus	   providing	   a	   pre-­‐invasive	  
pancreatic	   cancer	   model	   that	   offers	   interesting	   opportunities	   for	   chemoprevention	   and	   early	   detection	  
research.	   Indeed,	   serum	   samples	   from	   such	   mice	   are	   able	   to	   show	   specific	   changes	   in	   serum	   protein	  
profiles	   that	   could	   represent	   specific	   markers	   of	   pancreatic	   disease	   (see	   also	   next	   chapter).	   Additional	  
studies	  have	  demonstrated	  the	  specific	  role	  for	  signaling	  pathways,	  such	  as	  Hedgehog,	  EGF	  and	  Notch,	   in	  
regulating	  normal	  pancreatic	  development	  in	  the	  mouse	  and	  in	  both	  PanIN	  and	  invasive	  pancreatic	  cancer,	  
improving	  the	  understanding	  of	  human	  pancreatic	  cancer	  biology	  [130]	  and	  opening	  new	  perspectives	  for	  
targeted	  treatment	  of	  such	  a	  deadly	  malignancy.	  
	  
	  
Proteomics	  as	  a	  tool	  for	  the	  identification	  of	  new	  therapeutic	  targets.	  
The	  search	  for	  biomarkers	  by	  analyzing	  gene	  overexpression	  or	  protein	  elevation	   in	  pancreatic	   juice	  or	   in	  
sera	   has	   led	   to	   the	   identification	   of	   several	   tumor	   targets,	   including	  mesothelin,	   macrophage	   inhibitory	  
cytokine-­‐1	   (MIC-­‐1)	   and	   osteopontin	   [135].	   Various	   technologies	   have	   been	   recently	   employed	   for	   the	  
identification	   of	   candidate	   PDAC	   biomarkers	   using	   large-­‐scale	   analysis	   of	   antigen	   expression	   (based	   on	  
either	   RNA	   or	   protein	   levels).	   In	   particular,	   proteomic	   technologies	   have	   been	   used	   to	   detect	   antigens,	  
which	   can	   be	   resolved	   by	   two-­‐dimensional	   gel	   electrophoresis	   (2-­‐	   DE)	   and	   identified	   using	   Mass	  
Spectrometry	   and	   which	   elicit	   a	   humoral	   response	   in	   the	   sera	   of	   PDAC	   patients	   [136].	   Variants	   of	   this	  
approach	  for	  protein	  separation,	  selection	  and	  characterization	  have	  been	  described	  under	  different	  names	  
in	  the	  literature,	  such	  as	  SERPA	  [136]	  PROTEOMEX	  [137],	  or	  SPEAR	  [138].	  Lists	  of	  candidate	  PDAC-­‐specific	  
proteins	  have	  been	  generated	  on	  the	  basis	  of	  their	  elevated	  expression	  at	  the	  RNA	  level	  or	  of	   large-­‐scale	  
proteomic	  analysis	  of	  serum	  and/or	  pancreatic	  tissue	  samples	  (recently	  reviewed	  in	  [139]).	  
We	  have	  recently	  screened	  the	  reactivity	  of	  IgG	  in	  PDAC	  sera	  against	  proteins	  from	  PDAC	  cell	  lines	  (CF-­‐PAC-­‐
1	  and	  MIAPACA-­‐2)	  resolved	  by	  2-­‐DE.	  The	  reactivity	  of	  IgG	  from	  PDAC	  sera	  was	  compared	  to	  that	  of	  IgG	  from	  
sera	  of	  chronic	  pancreatitis	  (CP),	  non-­‐PDAC	  tumor	  patients	  and	  healthy	  subjects	  (HS).	  Approximately	  10	  to	  
60%	  of	  PDAC	  patient	  sera	  contain	  IgG	  against	  two	  functional	  kinds	  of	  proteins:	  metabolic	  enzymes,	  namely	  
α-­‐enolase	   (ENOA),	   triosephosphateisomerase	   1	   (TPIS),	   retinal	   dehydrogenase	   1	   (AL1A1),	   glucose-­‐6-­‐
phosphate	  1-­‐dehydrogenase	  (G6PD),	  elongation	  Factor	  Tu	  (EFTU),	  and	  isocitrate	  dehydrogenase	  (IDHC)	  and	  
cytoskeletal	   proteins,	   namely	   keratin	   10	   (K1C10),	   cofilin-­‐1	   (COF1)	   and	   transgelin	   (TAGL)	   [140,	   141,	   142].	  
Antibodies	   to	   these	  proteins	  were	  detected	  at	   very	   low	   frequency	   in	   sera	   from	  healthy	   subjects,	   chronic	  
pancreatis	  (CP),	  autoimmune	  and	  non-­‐PDAC	  tumor	  patients,	  suggesting	  that	  the	  antibody	  response	  to	  them	  
is	   characteristic	   of	   PDAC,	   although	   antibodies	   to	   some	   of	   these	   proteins	   are	   produced	   in	   other	   types	   of	  
cancer	  (such	  as	  antibodies	  to	  TPIS	  and	  K1C10	  in	  sera	  from	  lung	  and	  kidney	  cancer	  patients)	  [143,	  144].	  The	  
specificity	  of	  the	  antibody	  response	  for	  pancreatic	  cancer	  was	  further	  underlined	  by	  the	  observation	  that,	  
with	  the	  exception	  of	  AL1A1,	  all	  of	  the	  proteins	  recognized	  by	  antibodies	  in	  PDAC	  sera	  were	  upregulated	  in	  
PDAC	   biopsies	   [140,	   141],	   in	   agreement	   with	   data	   reporting	   TPIS,	   K1C10,	   EFTU,	   IDCH	   and	   COF1	  
overexpression	   in	   PDAC	   [144].	   An	   interesting	   point	   that	   comes	   from	   these	   studies	   is	   that	   PDAC	   is	  
characterized	  by	  an	  antibody	  response	  to	  the	  cytoskeletal	  proteins	  K1C10	  and	  COF1.	  In	  particular,	  the	  most	  
frequent	   antibody	   response	   of	   PDAC	   patients	   is	   directed	   against	   COF1,	   an	   actin	   depolymerizing	   protein	  
involved	  in	  invadopodium	  formation	  and	  required	  for	  tumor	  cells	  directionality	  in	  response	  to	  chemotactic	  
or	   growth-­‐factor	   stimulation	   [145].	   K1C10	   is	   also	   involved	   in	   the	   formation	   of	   the	   intermediate	   filament	  
cytoskeleton	  of	  all	  epithelial	  cells	  [146].	  Although	  autoantibodies	  to	  cytoskeletal	  proteins	  have	  been	  found	  
in	  cancer	  [147]	  autoantibodies	  to	  COF1	  in	  PDAC	  have	  not	  been	  described	  so	  far.	  Of	  interest,	  COF1	  might	  be	  
functionally	  associated	  with	  TPIS	  to	  feed	  glycolic	  fuel	  to	  Na,	  K	  ATPase	  [148].	  As	  the	  most	  frequent	  antibody	  
response	  in	  PDAC	  patients	  is	  directed	  to	  COF1	  and	  TPIS2,	  our	  data	  support	  the	  hypothesis	  that	  these	  two	  
proteins	  play	  a	  role	  in	  the	  biology	  of	  pancreatic	  cancer.	  
Interestingly,	   from	  a	   clinical	  perspective,	   another	  antigen	  highly	   recognized	  by	  PDAC	  patients	   [141,	  142],	  
ENOA,	   is	  also	  expressed	  on	  the	  surface	  of	  many	  cell	  types	   including	  PDAC	  where	   it	  acts	  as	  a	  plasminogen	  
receptor	  leading	  to	  extracellular	  matrix	  degradation	  and	  cell	  invasion	  [149].	  As	  cancer	  progression	  is	  often	  
associated	  with	   the	  ability	   to	  escape	   immune	   responses	   [150],	   the	   induction	  of	  autoantibody	  production	  
may	   reflect	   a	   more	   efficient	   immune	   response	   in	   PDAC	   patients.	   This	   hypothesis	   is	   supported	   by	   the	  
observation	  that	  the	  peripheral	  blood	  of	  PDAC	  patients	  with	  autoantibodies	  against	  ENOA	  contains	  ENOA-­‐
specific	   CD4+	   and	   CD8+	   T	   cells	   [141].	   In	   this	   context,	   the	   presence	   of	   autoantibodies	   to	   ENOA	   in	   PDAC	  
patients	  might	  directly	   reflect	   the	  activation	  of	  anti-­‐ENOA	  CD4+	  T	  helper	  cells.	  The	  expression	  of	  ENOA	   is	  
upregulated	  in	  PDAC	  at	  both	  the	  mRNA	  and	  protein	  levels	  [141,	  142,	  151,	  152].	  2-­‐DE	  and	  WB	  analysis	  with	  
an	   anti-­‐ENOA	   monoclonal	   antibody	   demonstrated	   that	   ENOA	   consists	   of	   six	   different	   isoforms	  
(ENOA1,2,3,4,5,6)	  with	  a	  similar	  47	  kDa	  molecular	  weight	  and	  pI	  ranging	  from	  6.6	  to	  8	  [142,	  153].	  A	  further	  
characterization	  of	   the	  each	  ENOA	   spots	   from	  PDAC	  and	  normal	  pancreatic	   duct	   cells	   by	   reversed-­‐phase	  
liquid	  chromatography	  nanospray	  tandem	  mass	  spectrometry	  (LC-­‐MS/MS)	  analysis	  identified	  multiple	  novel	  
post-­‐translational	  modifications	  of	  ENOA,	  such	  as	  phosphorylation,	  acetylation,	  and	  methylation	  [153].	  By	  
this	  approach,	  we	   identified	  for	  the	  first	   time	  a	  unique	  phosphosphoserine	  residue	   in	  the	  position	  419	  of	  
ENOA.	  By	  2-­‐DE	  WB	  we	  have	  found	  that	  phosphorylated	  ENOA1,2	   isoforms	  are	  preferentially	  expressed	   in	  
PDAC	   tissues	   and	   tumor	   cell	   lines	   and,	   to	   a	   lesser	   extent,	   in	   normal	   pancreatic	   tissues	   [142].	   Most	  
importantly,	   we	   have	   documented	   that	   ENOA1,2	   isoforms	   induce	   an	   in	   vivo	   humoral	   response	   in	   a	  
substantial	   proportion	   of	   PDAC	   patients	   (62%).	   We	   provided	   evidence	   that	   such	   reactivity	   is	   directed	  
against	   the	   phosphorylated	   residue	   and	   is	   specifically	   associated	   to	   PDAC,	   in	   that	   it	   is	   only	   sporadically	  
observed	   in	   patients	   with	   inflammatory	   pancreatic	   diseases	   (CP),	   autoimmunity,	   and	   patients	   with	   non-­‐
PDAC	  malignancies	  [142].	  Of	  clinical	  relevance,	  ENOA1,2	  autoantibodies	  are	  significantly	  more	  frequent	  in	  
patients	  with	  normal	  CA19.9	   levels,	  potentially	   complementing	   the	  performance	  of	   the	  most	  widespread	  
serological	   test	   currently	   employed	   in	   the	   diagnostic	  workup	  of	   both	   cystic	   and	   solid	   pancreatic	  masses.	  
Indeed,	   we	   have	   demonstrated	   that	   the	   combination	   of	   CA19.9	   and	   anti-­‐ENOA	   autoantibodies	   yields	   a	  
diagnostic	  accuracy	  of	  approximately	  95%,	  not	  only	   in	  advanced	  PDAC	  patients,	  but	  also	   in	  patients	  who	  
may	  be	  amenable	  to	  surgery	  with	  curative	  intent.	  Finally,	  anti-­‐ENOA1,2+	  patients	  exhibit	  a	  more	  favorable	  
clinical	  course	  with	  a	  significantly	   lower	  proportion	  of	  disease	  progression	  and	  a	  consequently	   longer	  PFS	  
upon	  gemcitabine	   treatment	   [142].	  This	   is	   clinically	   relevant	   in	  a	  disease,	   such	  as	  advanced	  PDAC,	  where	  
only	  performance	  status	  and	  disease	  stage	  have	  proved	  to	  reliably	  predict	  clinical	  outcome	  [154].	  
Further	   investigations	   are	   needed	   to	   validate	   PDAC	   sera	   reactivity	   against	   phosphorylated	   ENOA1,2	   and	  
other	   identified	  tumor	  associated	  antigens	   in	  a	   large-­‐scale	  study,	  as	  well	  as	   to	   fully	  evaluate	  their	  clinical	  
usefulness.	  
	  
Summary	  and	  conclusions.	  
Despite	   the	   disappointing	   clinical	   results	   obtained	   so	   far	   with	   molecularly	   targeted	   agents	   in	   advanced	  
PDAC,	  it	  is	  an	  exciting	  time	  for	  pancreatic	  cancer	  basic	  and	  translational	  research.	  Novel	  approaches,	  such	  
as	  molecular	  epidemiology	  and	  proteomics,	   are	  beginning	   to	   shed	   light	  on	  novel	  mechanisms	  underlying	  
pancreatic	  cancer	  initiation	  and	  progression	  and	  are	  likely	  to	  yield	  novel	  therapeutic	  targets	  to	  be	  tested	  in	  
the	   clinical	   setting.	  Moreover,	   the	   availability	   of	   recently	   developed,	   clinically	   relevant	   animal	  models	   of	  
PDAC	   [155,	   109]	   should	   now	  enable	   a	  more	   extensive	   preclinical	   testing	   of	   novel	   therapeutic	   strategies,	  
thereby	   allowing	   a	   more	   efficient	   selection	   of	   promising	   approaches	   for	   clinical	   testing	   and	   ultimately	  
increasing	  the	  rate	  of	  success	  of	  clinical	   trials	   testing	  novel	  agents	   for	  pancreatic	  cancer	   therapy.	  Exciting	  
developments	   in	   the	   understanding	   of	   the	   molecular	   and	   genetic	   bases	   of	   pancreatic	   cancer	   should	  
therefore	  raise	  renewed	  hope	  for	  all	  of	  our	  patients	  affected	  by	  such	  a	  devastating	  disease.	  
Table	  1.	  Sensitivity	  analysis	  of	  randomized	  trials	  comparing	  TA-­‐G	  vs	  G,	  according	  to	  the	  pathway	  targeted	  
by	  TA.	  	  
Pathway	   Ptsa	  (RCT)	   Outcome	   HR/RR	  (95%	  CI)	   p-­‐value	   Heterogeneity	  
(p-­‐value)	  
















































aPts:	   number	   of	   patients;	   RCT:	   number	   of	   randomized	   clinical	   trials;	   HR:	   hazard	   radio	   (for	   survival	  
outcomes);	  RR:	   relative	   risk	   (for	  overall	   response	   rate);	   CI:	   confidence	   intervals;	   EGFR:	   epidermal	   growth	  
factor	   receptor;	   MMP:	   matrix	   metallo-­‐proteases;	   FT:	   farnesyl	   transferase;	   VEGF:	   vascular	   endothelial	  
growth	  factor;	  OS:	  overall	  survival;	  PFS:	  progression	  free	  survival;	  ORR:	  overall	  response	  rate.	  	  	  
bInteraction	  p	  for	  OS	  =0.82	  
cInteraction	  for	  PFS	  =0.95	  
dInteraction	  p	  for	  ORR	  =0.33	  
	  	  
Table	  2.	  Inherited	  cancer	  syndromes	  at	  increased	  lifetime	  risk	  of	  developing	  PDAC.	  





Cancers	  common	  to	  the	  
syndrome	  
Peutz-­‐Jeghers	  syndrome	   STK11/LKB1	  (19p13.3)	   132	   4%	  
GI	   (esophagus,	   stomach,	  
pancreas,	   small	   and	   large	  
bowel),	  endometrium,	  ovary	  
testes,	  lung,	  breast	  
Hereditary	  pancreatitis	   PRSS1	  (7q35)	   ≥	  20	   n.a.	   Pancreas	  
Familial	  atypical	  multiple	  
mole	  melanoma	  (FAMMM)	  
P16INK4a/MTS1	  (9p21)	   13-­‐22	   98%	  
Benign	   nevi,	   malignant	  
melanoma,	   endometrial,	  









Breast,	   ovary,	   pancreas,	  
stomach,	   colon	   fallopian	  
tube,	   gallbladder,	   bile	   duct,	  
malignant	  melanoma	  
Hereditary	  nonpolyposis	  
colorectal	  cancer	  (HNPCC)	  
MSH2	  (2p22-­‐21)	  
MLH1	  (3p21.3)	  
n.a.	   4-­‐11%	  
Colorectal,	   pancreas,	   biliary	  
tract,	  papilla	  of	  Vater	  
Familial	  adenomatous	  
polyposis	  (FAP)	  
APC	  (5q21)	   ~	  5	   40%	  
Colorectal	   adenomas,	  
colorectal	  cancer,	  pancreas	  
	  
Figure	  legends.	  
Figure	  1.	  Forest	  plot	  analysis	  of	  OS	  results	  in	  randomized	  trials	  of	  TA-­‐G	  vs	  G.	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